Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study
Year: 2020
Type: article
Source: Blood
Authors: Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti, Marina Kremyanskaya, Jason Gotlib, Jeanne M. Palmer, Kelly McCaul, Vincent Ribrag, Adam J. Mead, Claire Harrison, Ruben Mesa, Jean-Jacques Kiladjian, Giovanni Barosi, Torsten G. Gerike, Jeevan K. Shetty, Joseph Pariseau, Gabriel Miranda, Martin Schwickart, Ana Carolina Giuseppi, Jennie Zhang, Jay T. Backstrom, Srdan Verstovsek
Institutions: Cleveland Clinic, Azienda Ospedaliero-Universitaria Careggi, University of Florence, University of Insubria, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Stanford Cancer Institute, Stanford University, Mayo Clinic, Mayo Clinic Hospital, Avera Health, Institut Gustave Roussy, Oxford University Hospitals NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Mays Cancer Center at UT Health San Antonio, Hôpital Saint-Louis, Université Paris Diderot, Policlinico San Matteo Fondazione, Bristol-Myers Squibb (United States), Acceleron Pharma (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3097057554